Dong Xiao

USPTO Granted Patents = 41 (Patent Applications = 18)

CIPO Patents = 2 (Patent Applications = 1)

EPO Patents = 25 (Patent Applications = 25)

Average Co-Inventor Count = 9.7

ph-index = 9

Forward Citations = 239(Granted Patents)

Location History:

Scotch Plains, NJ (US) (2002 - 2003)
Warran, NJ (US) (2010)
Somerset, NJ (US) (2020)
Warren, NJ (US) (2005 - 2022)

Company Filing History:

19 out of 2,405

Merck Sharp + Dohme Corp.

Schering-plough Corporation

where one patent can have more than one assignee

Years Active: 2002-2022

Loading Chart...

41 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 11352320 - Substituted [1.1.1] bicyclo compounds as indoleamine 2,3-dioxygenase inhibitors (2022-06-07),

2. 10968232 - Antidiabetic spirochroman compounds (2021-04-06),

3. 10968193 - Antidiabetic bicyclic compounds (2021-04-06),

4. 10688082 - Aminopyrazine compounds with A2A antagonist properties (2020-06-23),

5. 10138212 - [object Object] (2018-11-27),

6. 10059667 - Antidiabetic compounds (2018-08-28),

7. 10011615 - Heterobicyclo-substituted [1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with A2A anatagonist properties (2018-07-03),

8. 9969711 - [object Object] (2018-05-15),

9. 9957219 - Antidiabetic bicyclic compounds (2018-05-01),

10. 9840512 - Antidiabetic bicyclic compounds (2017-12-12),

11. 9688693 - [object Object] (2017-06-27),

12. 9676780 - [object Object] (2017-06-13),

13. 9549921 - Heterocyclic compounds and methods of use thereof for the treatment of hepatitis C (2017-01-24),

14. 9493461 - Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis C (2016-11-15),

15. 9469629 - [object Object] (2016-10-18),

Title: Innovator Spotlight: Dong Xiao - Pioneering Inventor from Warren, NJ

Introduction: Dong Xiao, a prolific inventor based in Warren, New Jersey, has made significant contributions to the field of pharmaceuticals with a remarkable 41 patents to his name.

Latest Patents: Among his recent patents, Dong Xiao has unveiled groundbreaking compounds such as substituted [1.1.1] bicyclo compounds as indoleamine 2,3-dioxygenase inhibitors. These compounds exhibit potential in treating or preventing IDO-associated diseases. Additionally, his work on antidiabetic bicyclic compounds, which act as agonists of G-protein coupled receptor 40 (GPR40), shows promise in managing Type 2 diabetes mellitus and related conditions.

Career Highlights: Dong Xiao has garnered experience and expertise from esteemed companies like Merck Sharp & Dohme Corporation and Schering Corporation, where he honed his skills in pharmaceutical research and development. His innovative approach to drug discovery has led to transformative solutions in healthcare.

Collaborations: Throughout his career, Dong Xiao has collaborated with notable peers such as Anandan Palani and Neng-Yang Shih, fostering a dynamic exchange of ideas and driving forward impactful research initiatives in the pharmaceutical industry.

Conclusion: Dong Xiao's pioneering work in inventing novel pharmaceutical compounds underscores his dedication to advancing healthcare solutions. With a proven track record of patents and collaborations, he continues to shape the landscape of pharmaceutical innovation, inspiring future generations in the field.

This text is generated by artificial intelligence and may not be accurate.